<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01478282</url>
  </required_header>
  <id_info>
    <org_study_id>FCRB</org_study_id>
    <secondary_id>2010-022985-29</secondary_id>
    <nct_id>NCT01478282</nct_id>
  </id_info>
  <brief_title>Reversal of the Antithrombotic Action of New Oral Anticoagulants</brief_title>
  <acronym>REVANT</acronym>
  <official_title>Evaluation of the Potential Action of Coagulation Factors Concentrates in the Reversal of the Antithrombotic Action of New Oral Anticoagulants: Studies ex Vivo in Blood Samples From Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gines Escolar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this study is to improve safety and efficiency of clinical practice with the&#xD;
      new generation of oral anticoagulants.&#xD;
&#xD;
        1. To determine the effect of new oral anticoagulants (dabigatran and rivaroxaban) on&#xD;
           platelets and coagulation mechanisms under flow conditions.&#xD;
&#xD;
        2. To evaluate the ability of the concentrates containing coagulation factors (PCCs and&#xD;
           FVIIa) to reverse the effects induced by the new anticoagulants.&#xD;
&#xD;
      These studies will be carried out ex vivo in blood samples obtained from healthy volunteers&#xD;
      undergoing oral anticoagulant therapy at doses of proven efficacy and safety used in previous&#xD;
      clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a lack of information on antidotes that could reverse the effects of new oral&#xD;
      anticoagulants in patients that require a rapid restoration of their impaired hemostatic&#xD;
      mechanisms. The present study seeks to improve the security and efficacy of the clinical&#xD;
      practice with the new generation of oral anticoagulants.&#xD;
&#xD;
      OBJECTIVES:&#xD;
&#xD;
        1. To assess the action of new oral anticoagulants (dabigatran y rivaroxaban) on hemostasis&#xD;
           with specific interest on possible interference with platelet interactions and&#xD;
           coagulation mechanisms under flow conditions;&#xD;
&#xD;
        2. To evaluate comparatively the effects of coagulation factor concentrates of established&#xD;
           efficacy (prothrombin complexes and rFVIIa) to reverse the alterations of hemostasis&#xD;
           parameters induced by the new anticoagulants.&#xD;
&#xD;
      METHODOLOGY:&#xD;
&#xD;
      Studies will be performed ex vivo using blood samples from healthy individuals subjected to&#xD;
      treatments with the new anticoagulants at doses of proven efficacy and safety (150mg/12 h for&#xD;
      dabigatran and 20 mg/day for rivaroxaban). Blood samples from the participants will be spiked&#xD;
      &quot;in vitro&quot; with know concentrations of the coagulation factors. Modifications in:&#xD;
&#xD;
        -  morphometric parameters (platelet deposition and fibrin formation) in perfusion studies&#xD;
           under flow conditions; and&#xD;
&#xD;
        -  analytical tests evaluating changes in coagulation mechanisms (thrombin generation,&#xD;
           ecarine and prothrombin times) will be determined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modifications in hemostasis parameters.</measure>
    <time_frame>5 days</time_frame>
    <description>We will evaluate: a) the surface covered by platelets and fibrin on the subendothelium of vascular segments. Platelet interaction will be expressed as percentage of covered surface by platelets (%CS) and classified as contact, adhesion and aggregates depending of the size of interactions. Fibrin formation will be also evaluated as percentage of surface covered by fibrin (%F) and as the mean area of fibrin formed; and b) thrombin generation as lag time and maximum thrombin peak generation using a commercially available test (Technothrombin TGA, Technoclone GMBH).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes observed after in vitro addition of coagulation factor concentrates</measure>
    <time_frame>5 days</time_frame>
    <description>We will re-evaluate: a) the surface covered by platelets and fibrin on the subendothelium of vascular segments. Platelet interaction will be expressed as percentage of covered surface by platelets (%CS) and classified as contact, adhesion and aggregates depending of the size of interactions. Fibrin formation will be also evaluated as percentage of surface covered by fibrin (%F) and as the mean area of fibrin formed; and b) thrombin generation as lag time and maximum thrombin peak generation using a commercially available test (Technothrombin TGA, Technoclone GMBH).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure other indirect biomarkers of the activation of the coagulation mechanisms.</measure>
    <time_frame>5 days</time_frame>
    <description>Prothrombin time, ecarin clotting time, and F1+2 fragments will be determined in frozen plasma samples.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Thrombosis</condition>
  <condition>Anticoagulant-induced Bleeding</condition>
  <condition>Anticoagulant Overdosage</condition>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy donors subjected to 20mg/day for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy volunteers subjected to 150 mg/12hours for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>20 mg/day, oral administration maintained for 5 days</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>Xarelto is the brand name for rivaroxaban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>150 mg/12 hours, administered orally, treatment maintained for 5 days</description>
    <arm_group_label>Dabigatran</arm_group_label>
    <other_name>Pradaxa is the brand name for dabigatran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers ages from 21 to 60 years&#xD;
&#xD;
          -  Approval informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hepatic or kidney disease&#xD;
&#xD;
          -  Previous history of hemorrhagic or thrombotic disease&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Concomitant use of drugs affecting hemostasis&#xD;
&#xD;
          -  Use of medications of herbal treatments that could interfere with the pharmacokinetics&#xD;
             or pharmacodynamics of the study drug (according to manufacturers label)&#xD;
&#xD;
          -  Practice of risky sports (during the study period)&#xD;
&#xD;
          -  Blood donation in the previous 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gines Escolar, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacio Clinic per a la Reçerca Biomedica (FCRB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic, Fundació Clinic (FCRB)</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gines Escolar</last_name>
      <phone>34932275448</phone>
      <email>gescolar@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Eduardo Arellano, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier Carne, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gines Escolar, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana M Galan, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Carlos Reverter, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaume Villalta, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>November 8, 2011</study_first_submitted>
  <study_first_submitted_qc>November 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <last_update_submitted>March 9, 2012</last_update_submitted>
  <last_update_submitted_qc>March 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Gines Escolar</investigator_full_name>
    <investigator_title>head of department Hemotherapy-Hemostasis</investigator_title>
  </responsible_party>
  <keyword>dabigatran</keyword>
  <keyword>rivaroxaban</keyword>
  <keyword>oral anticoagulants</keyword>
  <keyword>coagulation</keyword>
  <keyword>bleeding</keyword>
  <keyword>plasma concentrates</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 23, 2015</submitted>
    <returned>March 31, 2015</returned>
    <submitted>August 11, 2015</submitted>
    <returned>September 11, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

